Table 2.
Variables significantly associated with 1-year mortality according to sex.
| Men | Women | |||||||
|---|---|---|---|---|---|---|---|---|
| No event (n = 276) | Event (n = 32) | HR CI 95% | p-value | No event (n = 165) | Event (n = 26) | HR CI 95% | p-value | |
| Malignancy* | 55 (19%) | 13 (40.6%) | 2.66 [1.31; 5.39] | 0.007 | 28 (17.0%) | 6 (23.1%) | 1.51 [0.60; 3.76] | 0.377 |
| Hemoglobin (g/dl)* | 13.9 (1.66) | 12.1 (2.01) | 0.56 [0.47; 0.68] | <0.001 | 12.8 (1.32) | 12.3 (1.83) | 0.77 [0.58; 1.02] | 0.072 |
| Platelets (× 103 /μl)† | 178 (48.0) | 187 (64.8) | 1.00 [1.00; 1.01] | 0.331 | 205 (59.9) | 184 (52.9) | 0.99 [0.99; 1.00] | 0.035 |
| Lymphocites (× 103/μl)* | 1.92 (1.09) | 1.42 (0.59) | 0.38 [0.21; 0.69] | 0.001 | 2.08 (1.65) | 1.59 (0.76) | 0.64 [0.40; 1.02] | 0.058 |
| eGFR (ml/min/1.72 m2)* | 54.6 (17.1) | 45.0 (17.3) | 0.97 [0.95; 0.99] | 0.002 | 49.8 (17.5) | 48.3 (18.1) | 0.99 [0.97; 1.02] | 0.562 |
| Urea (mg/dl)* | 64.3 (30) | 81.5 (42) | 1.01 [1.00; 1.02] | 0.002 | 66.9 (31) | 77.1 (37) | 1.01 [1.00; 1.02] | 0.095 |
| Sodium (mEq/L)* | 141 (3) | 139 (4) | 0.81 [0.74; 0 0.91] | <0.001 | 141 (3) | 141 (3) | 1.00 [0.88; 1.13] | 0.968 |
| NT-proBNP (pg/ml)*† | 2586 (3272) | 6202 (7567) | 1.00 [1.00; 1.00] | <0.001 | 2437 (3388) | 3725 (3178) | 1.00 [1.00; 1.00] | 0.014 |
| Albumin (mg/dl)* | 4.15 (0.41) | 3.92 (0.50) | 0.27 [0.11; 0.65] | 0.003 | 4.10 (0.42) | 4.06 (0.44) | 0.55 [0.16; 1.92] | 0.348 |
| Non-dilated right ventricle (%)† | 224 (83.6%) | 25 (80.6%) | 0.80 [0.33; 1.95] | 0.626 | 146 (89.6%) | 12 (57.1%) | 0.20 [0.08; 0.47] | <0.001 |
| Systolic pulmonary artery pressure (mmHg)† | 38.6 (11.8) | 42.3 (12.2) | 1.03 [1.00; 1.06] | 0.072 | 38.8 (12.9) | 49.8 (20.1) | 1.03 [1.01; 1.05] | 0.004 |
| Significant tricuspid regurgitation† | 29 (10.7%) | 4 (12.9%) | 1.45 [0.51; 4.16] | 0.487 | 22 (13.6%) | 11 (42.3%) | 3.94 [1.80; 8.63] | 0.001 |
| Significant mitral regurgitation† | 39 (14.3%) | 8 (25.8%) | 1.91 [0.85; 4.27] | 0.116 | 18 (11.1%) | 8 (30.8%) | 4.31 [1.80; 10.3] | 0.001 |
| TAPSE (mm)*,† | 18.3 (4.1) | 16 (2.8) | 0.88 [0.79; 0.97] | 0.012 | 18.7 (3.7) | 16.7 (4.3) | 0.88 [0.79; 0.99] | 0.032 |
| Diuretic mean dose (mg of furosemide)*,† | 55.1 (36.2) | 80.8 (45.1) | 1.01 [1.01; 1.02] | 0.001 | 57.9 (32.3) | 78.0 (45.8) | 1.01 [1.00; 1.02] | 0.004 |
| Frailty (FRAIL)* | 37 (13.4%) | 10 (31.2%) | 3.18 (1.29–7.83) | 0.012 | 54 (32.7%) | 10 (38.5%) | 5.79 (0.74−45.3) | 0.094 |
| Frailty (CFS)* | 23 (8.33%) | 9 (28.1%) | 4.53 (2.08–9.89) | <0.001 | 36 (21.8%) | 5 (19.2%) | 0.84 (0.32- 2.24) | 0.732 |
| Frailty (mobility visual scale ≥2)* | 120 (43.5%) | 21 (65.6%) | 2.61 (1.26–5.43) | 0.010 | 107 (64.8%) | 21 (80.8%) | 2.35 (0.88–6.24) | 0.086 |
| Malnutrition (MNA-SF ≤11)* | 109 (39.5%) | 21 (65.6%) | 2.86 (1.38–5.94) | 0.005 | 87 (52.7%) | 18 (69.2%) | 1.98 (0.86–4.57) | 0.107 |
CFS, Clinical Frailty Scale; eGFR, estimated glomerular filtration rate; MNA-SF, Mini Nutritional Assessment Short Formulary; TAPSE, tricuspid annular plane systolic excursion.
*Variables significantly associated with 1-year mortality in men.
†Variables significantly associated with 1-year mortality in women.